Biotech News Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tnsaf who started this subject	7/18/2003 10:43:13 AM
From: Pied Piper	Read Replies (1) of 7143

Forbes Medi-Tech Signs International Reducol (TM) Sales and Licensing Agreement; Company Signs Reducol (TM) Agreement with Iljin Pharmaceuticals, South Korea Friday July 18, 8:01 am ET VANCOUVER, BRITISH COLUMBIA--Forbes Medi-Tech Inc. (TSX:FMI - News; NASDAQ:FMTI - News) is pleased to announce it has signed a licensing and sale agreement with Iljin Pharmaceuticals (Iljin) to supply Reducol(TM) for use in dietary supplements and functional food products in South Korea. "Iljin opens up an exciting opportunity for additional sales of Reducol(TM)," said Charles Butt, President and CEO of Forbes Medi-Tech Inc. "The dietary supplement and functional food market in South Korea is about to open up for the country's population, estimated at over 48 million. We believe Iljin has the necessary strengths to ensure the successful launch of Reducol(TM) into the Korean market," said Butt. biz.yahoo.com Piper

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next